Compare BUDA & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BUDA | CING |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.1M | 70.2M |
| IPO Year | 2025 | 2021 |
| Metric | BUDA | CING |
|---|---|---|
| Price | $5.30 | $4.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $13.00 | ★ $21.20 |
| AVG Volume (30 Days) | 6.8K | ★ 252.6K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.47 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $12,609,000.00 | N/A |
| Revenue This Year | $39.28 | N/A |
| Revenue Next Year | $21.29 | N/A |
| P/E Ratio | $37.93 | ★ N/A |
| Revenue Growth | ★ 11.84 | N/A |
| 52 Week Low | $5.26 | $3.16 |
| 52 Week High | $12.00 | $11.89 |
| Indicator | BUDA | CING |
|---|---|---|
| Relative Strength Index (RSI) | 30.36 | 47.67 |
| Support Level | N/A | $4.39 |
| Resistance Level | $7.86 | $5.35 |
| Average True Range (ATR) | 0.58 | 0.44 |
| MACD | -0.13 | 0.04 |
| Stochastic Oscillator | 3.33 | 48.44 |
Buda Juice Inc operates in a beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never heat-treated, pasteurized, never HPP- processed, never UV- treated and always cold.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.